Mari has over 35 years of experience in biopharmaceutical clinical development, encompassing a diverse range of therapeutic areas such as oncology, cardiovascular, CNS/neurology, and rare and ultra-rare diseases. Mari has extensive experience working in numerous rare and ultra-rare therapeutic disease areas and has comprehensive global experience in all phases of clinical development, including observational studies, Phases 1-3, post-approval development, and product lifecycle management. Mari has held multiple leadership position at innovative biopharmaceutical companies, including ESCAPE-Bio, QT-Ultrasound, BioMarin and Ultragenyx, where she made a signification contributed to the company’s early inception. Mari served at ICOS Corporation, which was later acquired by Eli Lilly & Company. During her tenure at ICOS, she held roles of increasing responsibility, contributing to the design and implementation of the clinical development strategy for the global development of Cialis®. In addition, Mari was at Poniard Pharmaceuticals (formerly NeoRx Corporation) for over 12 years, where she worked on novel cancer therapy products. Mari received a B.S. in nursing from Seattle Pacific University, graduating magna cum laude, and a B.S. in biology from the University of Puget Sound.